Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 expression + EGFR mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials ESMO Asia 2022 - 1 week (New C3) aumolertinib Sensitive : C3 ESMO Asia 2022 - 1wk	aumolertinib Sensitive: C3 – Early Trials ESMO Asia 2022 - 1 week aumolertinib Sensitive : C3 ESMO Asia 2022 - 1 week - (New C3)
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4